Vitamin D supplements don't improve liver healing in chronic hepatitis C: Study
Thailand: Short-term supplementation of vitamin D in chronic hepatitis C (CHC) patients after DAA treatment does not expedite the process of residual liver fibrosis healing or improve serum fibrogenesis, finds a recent study. The results are published in the journal PeerJ.
In patients with CHC, the replacement of vitamin D with chronic hepatitis C before viral eradication, has shown a protective effect on serum markers associated with hepatic fibrogenesis. Supachaya Sriphoosanaphan, Chulalongkorn University, Bangkok, Thailand, and colleagues, therefore, hypothesized that vitamin D may facilitate further fibrosis amelioration following curative treatment with direct-acting antivirals (DAA).
For the purpose, the researchers conducted a randomized, double-blind, placebo-controlled trial between February 2018 and August 2018. It included 75 patients with CHC and vitamin D deficiency. They were randomized the ratio of 1:1 to receive either ergicalciferol (n=37) or placebo over 6 weeks (n=38).
The researchers analyzed biochemical analysis indicators, including 25-hydroxyvitamin D (25(OH)D), fibrogenic markers [(transforming growth factor beta 1 (TGF-β1) and tissue inhibitors of matrix metalloproteinases 1 (TIMP-1)], and fibrolytic markers [matrix metalloproteinase 9 (MMP-9) and amino terminal type III procollagen peptide (P3NP)] at baseline and at 6 weeks. Serum 25(OH)D was analyzed by a chemiluminescence immunoassay. Serum hepatic fibrogenesis markers were measured using a quantitative sandwich enzyme-linked immunosorbent assay.
Key findings of the study include:
- At the end of the study, the mean serum 25(OH)D level had risen to a normal level in the VD group, but was still deficient in the placebo group (41.8 ± 9.1 vs. 18.1 ± 4.6 ng/mL).
- Upon restoration of the VD level, there were no significant mean differences in the change from baseline for TGF-β1 (−0.6 ng/mL), TIMP-1 (−5.5 ng/mL), MMP-9 (122.9 ng/mL), and P3NP (−0.1 ng/mL) between the VD and placebo groups.
"Future studies are warranted to evaluate the long-term effect of VD supplementation on hepatic fibrosis regression," concluded the authors.
The study titled, "Effect of vitamin D supplementation in patients with chronic hepatitis C after direct-acting antiviral treatment: a randomized, double-blind, placebo-controlled trial," is published in the journal PeerJ.
DOI: https://peerj.com/articles/10709/
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.